Relmada Therapeutics, Inc. RLMD Proceeds From Sale Of Short Term Investments
Proceeds From Sale Of Short Term Investments at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s proceeds from sale of short term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s proceeds from sale of short term investments?
- Relmada Therapeutics, Inc. (RLMD) reported proceeds from sale of short term investments of $14.29M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s proceeds from sale of short term investments changed year-over-year?
- Relmada Therapeutics, Inc.'s proceeds from sale of short term investments decreased by 9.8% year-over-year, from $15.85M to $14.29M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s proceeds from sale of short term investments?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s proceeds from sale of short term investments has grown at a -32.2% compound annual growth rate (CAGR), from $168.86M to $35.69M.